SMS-oncology Announces Changes to the Management Team
News Feb 04, 2013
Members are: Edwin Klumper (Chief Executive Officer, CEO), Philine van den Tol (Chief Operating Officer, COO), Eric van der Putten (Chief Business Development Officer, CBDO), Wouter Wijker (Managing Director Biometrics Unit), and Raymond Hoffmans (Director Consultancy).
The new CEO Edwin Klumper will succeed Eric van der Putten who will take on the position of CBDO. In his new role Eric will be responsible for driving new business opportunities and growing our client base. Edwin Klumper stated: "All credits go to Eric van der Putten who has been the driving force into building a fully GCP compliant CRO from scratch within five years that has resulted into ISO 9001:2008 certification in 2012. Our clients will benefit discussing their new cancer studies with Eric who brings to the table 30+ years of experience in running phase I and II cancer trials in close collaboration with the top tier of oncologists. His experience and operational insights will be of great value to our clients in achieving their objectives.”
Philine van den Tol has been promoted to the position of COO. With her no-nonsense and can-do attitude Philine motivates and leads by example the operational staff of SMS-oncology. She knows what it takes to run multiple multicenter cancer studies from her past experience as project manager for the Dutch Breast Cancer Trialists’ Group. The Management Team is completed by Raymond Hoffmans (Director Consultancy) and Wouter Wijker (Managing Director Biometrics Unit).
We thank Erik Leferink who has been leading in the foundation of SMS-oncology. Erik will hand over his business development responsibilities to Eric van der Putten. As a serial entrepreneur Erik will reallocate his time to grow new ventures that he has recently established. Erik will remain active as a shareholder of SMS-oncology.
“These changes reflect our steady growth and mark our next step”, said Edwin Klumper. “After 5 years of serving over 50 clients, building a highly motivated and oncology experienced staff, expanding our trial base across Europe, collaborating with top oncology centers, we are ready for our next step and ambition to become a European premier oncology CRO. It is a privilege to lead such a good team and serve our clients to jointly improve cancer treatment by developing new drugs that are desperately needed by so many patients".
Key Cancer-Linked Proteins Thought to be ‘Undruggable’ Until NowNews
A new study published in Nature, conducted by an alliance between industry and academia involving the University of Liverpool, highlights a new approach to targeting key cancer-linked proteins, thought to be ‘undruggable’.READ MORE
Arsenic Trioxide Could Extend Lives of Patients with Aggressive Brain CancerNews
Arsenic trioxide could be a powerful therapy that could extend the lives of certain glioblastoma patients by as much as three to four times the median expectation.READ MORE